Precigen, Inc. (PGEN): Price and Financial Metrics


Precigen, Inc. (PGEN): $4.57

-0.02 (-0.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 508

in industry

PGEN POWR Grades


  • Momentum is the dimension where PGEN ranks best; there it ranks ahead of 69.06% of US stocks.
  • The strongest trend for PGEN is in Growth, which has been heading down over the past 52 weeks.
  • PGEN ranks lowest in Value; there it ranks in the 6th percentile.

PGEN Stock Summary

  • With a price/sales ratio of 9.35, Precigen Inc has a higher such ratio than 80.88% of stocks in our set.
  • With a year-over-year growth in debt of -23.29%, Precigen Inc's debt growth rate surpasses merely 21.91% of about US stocks.
  • Precigen Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -12.8%, greater than the shareholder yield of merely 18.51% of stocks in our set.
  • Stocks that are quantitatively similar to PGEN, based on their financial statements, market capitalization, and price volatility, are FICO, PRCH, PD, CLIR, and OTRK.
  • PGEN's SEC filings can be seen here. And to visit Precigen Inc's official web site, go to www.precigen.com.

PGEN Valuation Summary

  • PGEN's price/earnings ratio is -11.5; this is 131.51% lower than that of the median Healthcare stock.
  • PGEN's price/sales ratio has moved down 2887.8 over the prior 98 months.
  • PGEN's price/sales ratio has moved down 2887.8 over the prior 98 months.

Below are key valuation metrics over time for PGEN.

Stock Date P/S P/B P/E EV/EBIT
PGEN 2021-08-31 12.4 7.9 -11.5 -15.6
PGEN 2021-08-30 12.2 7.7 -11.3 -15.3
PGEN 2021-08-27 12.3 7.8 -11.4 -15.5
PGEN 2021-08-26 12.1 7.7 -11.2 -15.2
PGEN 2021-08-25 11.9 7.5 -11.0 -15.0
PGEN 2021-08-24 11.9 7.6 -11.1 -15.1

PGEN Growth Metrics

  • Its 4 year cash and equivalents growth rate is now at -74.03%.
  • Its 4 year net income to common stockholders growth rate is now at -80.44%.
  • The year over year net income to common stockholders growth rate now stands at 58.49%.
Over the past 33 months, PGEN's revenue has gone down $93,410,000.

The table below shows PGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 101.007 -59.633 -108.537
2021-03-31 97.851 -65.662 -131.841
2020-12-31 103.178 -77.021 -170.521
2020-09-30 92.203 -92.694 -298.075
2020-06-30 91.663 -100.838 -322.201
2020-03-31 97.225 -120.436 -317.613

PGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PGEN has a Quality Grade of C, ranking ahead of 33.55% of graded US stocks.
  • PGEN's asset turnover comes in at 0.277 -- ranking 451st of 561 Business Services stocks.
  • FTAI, V, and GOVX are the stocks whose asset turnover ratios are most correlated with PGEN.

The table below shows PGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.277 0.456 -0.241
2021-03-31 0.276 0.439 -0.310
2020-12-31 0.291 0.462 -0.418
2020-09-30 0.237 0.398 -0.717
2020-06-30 0.201 0.376 -0.731
2020-03-31 0.183 0.387 -0.659

PGEN Price Target

For more insight on analysts targets of PGEN, see our PGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.00 Average Broker Recommendation 1.5 (Moderate Buy)

PGEN Stock Price Chart Interactive Chart >

Price chart for PGEN

PGEN Price/Volume Stats

Current price $4.57 52-week high $11.10
Prev. close $4.59 52-week low $3.95
Day low $4.51 Volume 725,300
Day high $4.68 Avg. volume 1,322,266
50-day MA $5.40 Dividend yield N/A
200-day MA $6.78 Market Cap 944.36M

Precigen, Inc. (PGEN) Company Bio


Precigen, Inc. (formerly Intrexon Corporation) provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. The company was founded in 1998 and is based in Germantown, Maryland.


PGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

PGEN Latest Social Stream


Loading social stream, please wait...

View Full PGEN Social Stream

Latest PGEN News From Around the Web

Below are the latest news stories about Precigen Inc that investors may wish to consider to help them evaluate PGEN as an investment opportunity.

Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Harry Thomasian Jr. as the Company's chief financial officer (CFO), effective October 18, 2021. Mr. Thomasian will oversee the Company's corporate financial strategy and planning, and provide a critically important strategic perspective to business development, licensing, and corporate financing initi

Yahoo | October 12, 2021

Here are Greater Washington's highest-paid public company CEOs

We have a pretty different lineup of public company CEOs this year, especially looking at just the highest-paid in 2020. Several new CEOs have taken the reins over the past year at some of the region’s biggest companies, including James Taiclet at Lockheed Martin Corp. (NYSE: LMT), Rainer Blair at Danaher Corp. (NYSE: DHR), Mike Salvino at DXC Technology Co. (NYSE: DXC) and Helen Sabzevari at Precigen Inc. (NASDAQ: PGEN).

Yahoo | October 5, 2021

Implied Volatility Surging for Precigen (PGEN) Stock Options

Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.

Yahoo | October 4, 2021

Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced additional positive interim data from the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes (T1D) (clinical trial identifier: NCT03751007, EudraCT 2017-002871-24). Results were presented in an oral presentation entitled, "AG

Yahoo | October 1, 2021

What Kind Of Investors Own Most Of Precigen, Inc. (NASDAQ:PGEN)?

A look at the shareholders of Precigen, Inc. ( NASDAQ:PGEN ) can tell us which group is most powerful. Institutions...

Yahoo | September 21, 2021

Read More 'PGEN' Stories Here

PGEN Price Returns

1-mo -13.61%
3-mo -19.82%
6-mo -44.40%
1-year 11.46%
3-year -61.07%
5-year -82.50%
YTD -55.20%
2020 86.13%
2019 -16.21%
2018 -43.23%
2017 -52.59%
2016 -19.40%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8826 seconds.